<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714749</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A02799-30</org_study_id>
    <nct_id>NCT04714749</nct_id>
  </id_info>
  <brief_title>Feasibility and Tolerance Study for the Treatment of Varicose Ulcers by Cyanoacrylate Glue (ETUVVE)</brief_title>
  <acronym>ETUVVE</acronym>
  <official_title>Feasibility and Tolerance Study for the Treatment of Varicose Ulcers by Cyanoacrylate Glue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Pasteur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ulcers of the lower limbs are a major public health problem whose management needs to be&#xD;
      further improved, particularly in terms of healing time, prevalence and recurrence rate.&#xD;
      Ulcers of venous origin, or mixed arteriovenous and predominantly venous, represent the&#xD;
      majority of leg ulcers with an estimated proportion of 70 to 80% of cases. These are painful,&#xD;
      disabling conditions that are difficult to treat in a lasting way.&#xD;
&#xD;
      This study focuses on a treatment strategy with endovascular glue. The advantage of treating&#xD;
      ulcers with cyanoacrylate glue is the possibility of occluding the great saphenous vein over&#xD;
      its entire length, freeing itself from neurological complications secondary to endovenous&#xD;
      thermal techniques (laser, radiofrequency), as well as the possibility of treating by direct&#xD;
      puncture any perforators or tributaries feeding the ulcer.&#xD;
&#xD;
      This treatment strategy would improve the healing process for a lasting resolution of this&#xD;
      pathology. This study aims to describe the feasibility and tolerance of this type of&#xD;
      treatment in the resolution of varicose ulcers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ulcer healing</measure>
    <time_frame>Between surgery and 12 months after</time_frame>
    <description>Proportion of patients who presented with healing of the venous ulcer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional and technical success</measure>
    <time_frame>Day 0, Day 8, Month 1, Month 6 , Month 12</time_frame>
    <description>Success assessed by occlusion of treated veins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Pain</measure>
    <time_frame>Day 0, Day 8, Month 1, Month 6 , Month 12</time_frame>
    <description>Visual analogue scale (0-100 mm); higher is worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity</measure>
    <time_frame>Day 0, Day 8, Month 1, Month 6 , Month 12</time_frame>
    <description>Clinical Venous Severity Score (CVSS); score between 0 to 30; higher is worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing</measure>
    <time_frame>Between surgery and 12 months after</time_frame>
    <description>Time to ulcer healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ulcer duration</measure>
    <time_frame>Between surgery and 12 months after</time_frame>
    <description>Time without ulcer; time to recurrence (in days )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ulcer recurrence</measure>
    <time_frame>Between surgery and 12 months after</time_frame>
    <description>Rate of recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>Day 0, Day 8, Month 1, Month 6 , Month 12</time_frame>
    <description>VEINES Sym (VEnous INsufficiency Epidemiologic and Economic Study - Symptoms) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of Life</measure>
    <time_frame>Day 0, Day 8, Month 1, Month 6 , Month 12</time_frame>
    <description>VEINES QOL (VEnous INsufficiency Epidemiologic and Economic Study- Quality Of Life) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 0, Day 8, Month 1, Month 6 , Month 12</time_frame>
    <description>Adverse events related to glue or to the endovenous intervention</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>Endovenous treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endovenous treatment with cyanoacrylate glue</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovenous treatment</intervention_name>
    <description>Treatment of great saphenous vein (its tributaries and possible incompetent perforators feeding the ulcer) by endovascular cyanoacrylate glue</description>
    <arm_group_label>Endovenous treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cyanoacrylate glue</intervention_name>
    <description>Treatment of great saphenous vein (its tributaries and possible incompetent perforators feeding the ulcer) by endovascular cyanoacrylate glue</description>
    <arm_group_label>Endovenous treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary insufficiency of the great saphenous vein (GVS) by a reflux&gt; 0.5 second from&#xD;
             the inter-fascial saphenous trunk to the upper 1/3 of the thigh extending over the&#xD;
             entire height of the thigh either in the saphenous compartment or in at least one&#xD;
             extra-fascial tributary, in a standing patient, by compression of the calf&#xD;
&#xD;
          -  CEAP: C6, ulcer present on a single leg whose size can be captured by a simple&#xD;
             photograph&#xD;
&#xD;
          -  Diameter of the GVS at the saphenofemoral junction ≥3 or ≤12 millimeters&#xD;
&#xD;
          -  Patient affiliated or beneficiary of a social security scheme&#xD;
&#xD;
          -  Patient having signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a circumferential ulcer&#xD;
&#xD;
          -  Patient with ipsilateral small saphenous vein insufficiency&#xD;
&#xD;
          -  Presenting a serious current pathology and / or a life expectancy of less than 5 years&#xD;
&#xD;
          -  History of deep or superficial vein thrombosis in the previous 6 months&#xD;
&#xD;
          -  Patient with arteriopathy obliterating of the affected lower limb, with an IPS &lt;0.8&#xD;
             or&gt; 1.3&#xD;
&#xD;
          -  With post-thrombotic obstructive syndrome in the popliteal and / or femoral and / or&#xD;
             iliac stage on the ipsilateral lower limb&#xD;
&#xD;
          -  Presenting primary or post-thrombotic axial deep venous reflux on the ipsilateral&#xD;
             lower limb&#xD;
&#xD;
          -  Suspicion of non-post-thrombotic iliac compression on Doppler ultrasound&#xD;
&#xD;
          -  Contraindication to the intended treatment technique&#xD;
&#xD;
          -  Known allergy to cyanoacrylate glue or xylocaine&#xD;
&#xD;
          -  Patient with a BMI greater than 40 (morbid obesity)&#xD;
&#xD;
          -  Patient whose geographical distance is not compatible with the follow-up of the study&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patient participating in another clinical study&#xD;
&#xD;
          -  Patient linguistically or psychically unable to understand the information given, to&#xD;
             give informed consent or to answer the study questionnaires.&#xD;
&#xD;
          -  Protected patients: Adults under some guardianship or other legal protection;&#xD;
             Hospitalized without consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas NEAUME, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas NEAUME, MD</last_name>
    <phone>+33 5 61 16 13 01</phone>
    <email>nneaume@clinique-pasteur.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Pasteur Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas NEAUME, MD</last_name>
      <phone>+33 5 61 16 13 01</phone>
      <email>nneaume@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Nicolas NEAUME, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence ALLOUCHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clélia DORNIER-CASSAGNEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fannie FORGUES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe LEGER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gohel MS, Barwell JR, Taylor M, Chant T, Foy C, Earnshaw JJ, Heather BP, Mitchell DC, Whyman MR, Poskitt KR. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ. 2007 Jul 14;335(7610):83. Epub 2007 Jun 1.</citation>
    <PMID>17545185</PMID>
  </reference>
  <reference>
    <citation>Gohel MS, Heatley F, Liu X, Bradbury A, Bulbulia R, Cullum N, Epstein DM, Nyamekye I, Poskitt KR, Renton S, Warwick J, Davies AH; EVRA Trial Investigators. A Randomized Trial of Early Endovenous Ablation in Venous Ulceration. N Engl J Med. 2018 May 31;378(22):2105-2114. doi: 10.1056/NEJMoa1801214. Epub 2018 Apr 24.</citation>
    <PMID>29688123</PMID>
  </reference>
  <reference>
    <citation>Hirsch T. Varicose vein therapy and nerve lesions. Vasa. 2017 Mar;46(2):96-100. doi: 10.1024/0301-1526/a000588. Epub 2016 Dec 16.</citation>
    <PMID>27981883</PMID>
  </reference>
  <reference>
    <citation>Toonder IM, Lam YL, Lawson J, Wittens CH. Cyanoacrylate adhesive perforator embolization (CAPE) of incompetent perforating veins of the leg, a feasibility study. Phlebology. 2014 May;29(1 suppl):49-54. Epub 2014 May 19. Review.</citation>
    <PMID>24843086</PMID>
  </reference>
  <reference>
    <citation>Morrison N, Gibson K, Vasquez M, Weiss R, Jones A. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2020 Nov;8(6):978-989. doi: 10.1016/j.jvsv.2019.12.080. Epub 2020 Mar 20.</citation>
    <PMID>32205125</PMID>
  </reference>
  <reference>
    <citation>Heatley F, Onida S, Davies AH. The global management of leg ulceration: Pre early venous reflux ablation trial. Phlebology. 2020 Sep;35(8):576-582. doi: 10.1177/0268355520917847. Epub 2020 Apr 8.</citation>
    <PMID>32268842</PMID>
  </reference>
  <reference>
    <citation>Abenhaim L, Kurz X. The VEINES study (VEnous Insufficiency Epidemiologic and Economic Study): an international cohort study on chronic venous disorders of the leg. VEINES Group. Angiology. 1997 Jan;48(1):59-66.</citation>
    <PMID>8995345</PMID>
  </reference>
  <reference>
    <citation>Lamping DL, Schroter S, Kurz X, Kahn SR, Abenhaim L. Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. J Vasc Surg. 2003 Feb;37(2):410-9.</citation>
    <PMID>12563215</PMID>
  </reference>
  <reference>
    <citation>Kahn SR, Lamping DL, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Shrier I; VETO Study investigators. VEINES-QOL/Sym questionnaire was a reliable and valid disease-specific quality of life measure for deep venous thrombosis. J Clin Epidemiol. 2006 Oct;59(10):1049-56. Epub 2006 Jun 23. Erratum in: J Clin Epidemiol. 2006 Dec;59(12):1334.</citation>
    <PMID>16980144</PMID>
  </reference>
  <reference>
    <citation>Bland JM, Dumville JC, Ashby RL, Gabe R, Stubbs N, Adderley U, Kang'ombe AR, Cullum NA. Validation of the VEINES-QOL quality of life instrument in venous leg ulcers: repeatability and validity study embedded in a randomised clinical trial. BMC Cardiovasc Disord. 2015 Aug 11;15:85. doi: 10.1186/s12872-015-0080-7.</citation>
    <PMID>26260973</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Pasteur</investigator_affiliation>
    <investigator_full_name>Nicolas NEAUME</investigator_full_name>
    <investigator_title>Principal investigator, MD</investigator_title>
  </responsible_party>
  <keyword>endovenous treatment</keyword>
  <keyword>glue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

